Send to

Choose Destination
J Pediatr Gastroenterol Nutr. 2016 Dec;63(6):676-680.

Effect of Oral Lipid Matrix Supplement on Fat Absorption in Cystic Fibrosis: A Randomized Placebo-Controlled Trial.

Author information

*Division of Gastroenterology, Hepatology and Nutrition, The Children's Hospital of Philadelphia †Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia ‡Community Health Sciences, University of Calgary, Calgary, Alberta, Canada §Stockton University, Pomona, NJ ||Center for Adherence and Self-Management, Cincinnati Children's Hospital Medical Center ¶Department of Pediatrics, Division of Behavioral Medicine and Clinical Psychology, University of Cincinnati College of Medicine, Cincinnati, OH #Westat Biostatistics and Data Management Core, Children's Hospital of Philadelphia, Philadelphia, PA **Avanti Polar Lipids, Inc, Alabaster, AL.


Pancreatic enzyme therapy does not normalize dietary fat absorption in patients with cystic fibrosis and pancreatic insufficiency. Efficacy of LYM-X-SORB (LXS), an easily absorbable lipid matrix that enhances fat absorption, was evaluated in a 12-month randomized, double-blinded, placebo-controlled trial with plasma fatty acids (FA) and coefficient of fat absorption (CFA) outcomes. A total of 110 subjects (age 10.4 ± 3.0 years) were randomized. Total FA increased with LXS at 3 and 12 months (+1.58, +1.14 mmol/L) and not with placebo (P = 0.046). With LXS, linoleic acid (LA) increased at 3 and 12 months (+298, +175 nmol/mL, P ≤ 0.046), with a 6% increase in CFA (P < 0.01). LA increase was significant in LXS versus placebo (445 vs 42 nmol/mL, P = 0.038). Increased FA and LA predicted increased body mass index Z scores. In summary, the LXS treatment improved dietary fat absorption compared with placebo as indicated by plasma FA and LA and was associated with better growth status.


[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

and Sources of Funding: Supported by NIDDK (R44DK060302), and the Nutrition Center at the Children’s Hospital of Philadelphia. The project described was supported by the National Center for Research Resources, Grant UL1RR024134, and is now at the National Center for Advancing Translational Sciences, Grant UL1TR000003. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. VAS, JIS, AM, BNA, MRM, KAD, KH, JR, and OUE have no financial disclosures or potential conflicts of interest. WAS, President of Avanti Polar Lipids, Inc. was the principal investigator of the NIH Small Business Innovation Research (SBIR) award.

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center